Incyte INCY Europe — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's europe — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's europe — total revenues?
- Incyte (INCY) reported europe — total revenues of $92.43M in Q1 2026.
- How has Incyte's europe — total revenues changed year-over-year?
- Incyte's europe — total revenues increased by 34.7% year-over-year, from $68.61M to $92.43M.
- What is the long-term trend for Incyte's europe — total revenues?
- Over 4 years (2021 to 2025), Incyte's europe — total revenues has grown at a 27.1% compound annual growth rate (CAGR), from $124.1M to $323.73M.
- What does europe — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products and licensing arrangements within the European geographic segment. It reflects the commercial success and market penetration of the company's oncology and dermatology portfolio in this specific region. This figure is a primary indicator of regional growth and the effectiveness of local distribution and partnership strategies.